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Multiligand receptors
The multiligand receptors that form the focus of this
Perspective series have expectedly diverse functions,
often conforming to potential gaps in the host
response to invading pathogens that are not effective-
ly manned by adaptive immunity. For example, the
macrophage scavenger receptor (type A) interacts with
bacterial cell walls and enhances clearance of Gram-
negative bacteria from the circulation (1). Similarly, the
macrophage mannose receptor binds mannose-rich
carbohydrates typical of many microorganisms, there-
by promoting their cellular uptake and disposal (2).
The present contribution to the series concerns a mem-
ber of the immunoglobulin superfamily that differs
from the above molecules in that all known ligands in
its broad repertoire can be generated endogenously (3).
This cell surface protein, called RAGE because it serves
as a receptor for nonenzymatically glycated adducts
termed “advanced glycation endproducts” (AGEs), also
binds β-sheet fibrils characteristic of amyloid; proin-
flammatory cytokine–like mediators of the S100/cal-
granulin family; and amphoterin, a nuclear protein
sometimes found in the ECM (Table 1).
Binding of these ligands to RAGE does not accelerate
clearance or degradation but rather begins a sustained
period of cellular activation mediated by receptor-
dependent signaling. This is the first of several distinc-
tive themes that have emerged from studies of RAGE.
Other unusual features of the receptor include its abil-
ity to engage classes of molecules, rather than individ-
ual ligands, and its enhanced surface expression in
environments rich in RAGE ligands. This last point is
crucial, since it explains how upregulation of this recep-
tor can contribute to an ascending spiral of RAGE-
dependent cellular perturbation. Taken together, these
features of RAGE allow the receptor to propagate cel-
lular dysfunction in a number of pathophysiologically
relevant situations, most often dictated by the forma-
tion and persistence of ligands in the tissues. As
described below, these diverse situations range from
the complications of diabetes and cellular perturbation
in amyloidoses to immune and inflammatory respons-
es and tumor cell behavior.
RAGE and the complications of diabetes
Nonenzymatic glycoxidation of macromolecules ulti-
mately resulting in the formation of AGEs is enhanced
at sites of inflammation, in renal failure, in the presence
of hyperglycemia, and under other conditions associat-
ed with systemic or local oxidant stress (4). Accumula-
tion of AGEs in the vasculature can occur focally, as in
the joint amyloid composed of AGE-β2-microglobulin
found in patients with dialysis-related amyloidosis (5),
or generally, as exemplified by the vasculature and tis-
sues of patients with diabetes (6). The progressive accu-
mulation of AGEs in patients with diabetes suggests that
endogenous clearance mechanisms fail to function effec-
tively at sites of AGE deposition. Such deposited AGEs
have the capacity to alter cellular properties by a number
of mechanisms. Direct effects of AGEs in the extracellu-
lar space include formation of crosslinks that can also
trap neighboring unrelated macromolecules (4). Nonen-
zymatic glycation has been shown to alter properties of
FGF, as well as vitronectin and laminin (4). However,
AGE engagement of cellular receptors would provide a
biologic amplification mechanism whereby glycoxidized
adducts could modulate properties of multiple cells.
RAGE was first identified from tissue homogenates
based on its capacity to bind a glycoxidized form of
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albumin prepared in vitro (7). Its extracellular domain
consists of three immunoglobulin-like regions, one
“V”-type followed by two “C”-type (8). RAGE contains
a single transmembrane-spanning domain and a
43–amino acid cytosolic tail. Structure-function stud-
ies have shown that the V-domain is critical for ligand
binding and that the cytosolic tail is essential for
RAGE-mediated intracellular signalling (Figure 1). A
truncated form of RAGE, which lacks the cytosolic tail,
remains firmly embedded in the membrane. Although
this form of the receptor is competent to bind the usual
complement of RAGE ligands, it acts as a dominant
negative (termed “DN-RAGE”) receptor, and its expres-
sion strikingly suppresses RAGE-mediated signaling,
even in cells bearing the full-length form (9, 10).
RAGE is expressed at low levels in normal tissues and
vasculature. However, the receptor becomes upregulat-
ed wherever its ligands accumulate (11–13). In diabet-
ic vessels, for example, RAGE ligands include AGEs of
at least two types, (carboxymethyl)lysine adducts
and hydroimidazolones (14), and S100/calgran-
ulins as well. RAGE expression is increased in
endothelium, smooth muscle cells, and infiltrating
mononuclear phagocytes in diabetic vasculature. The
overlapping expression of RAGE and its ligands led us
to consider the possibility that RAGE mediates cellular
activation in diabetic vessels. Indeed, studies in cell cul-
ture show that AGE-RAGE interaction alters cellular
properties important in vascular homeostasis (15–17).
For example, following engagement of RAGE by AGEs,
endothelia increase their expression of VCAM-1, tissue
factor, and IL-6, and their permeability to macromole-
cules (18–20). AGE-RAGE–mediated activation of the
transcription factor NF-κB is likely to explain these
observations, at least in part (20, 21). In mononuclear
phagocytes, RAGE activates expression of cytokines
and growth factors and induces cell migration in
response to soluble AGEs, whereas haptotaxis occurs
with immobilized ligands (22).
These considerations led us to propose the following
two-hit model for RAGE-mediated perturbation of cel-
lular properties in diabetic vasculature: the presence of
ligands for RAGE changes properties of the vascula-
ture, resulting in a basal state of activation/dysfunction
(first hit; Figure 2); with a superimposed stimulus, such
as deposition of oxidized lipoproteins, infection, or
ischemia, cellular responses favor derangement of vas-
cular function and tissue damage, rather than restitu-
tion of homeostasis (second hit; Figure 2).
Diabetic macrovascular disease provides an especial-
ly important situation to test this model, as epidemio-
logic studies have suggested that factors other than
glycemia and those traditionally associated with ather-
osclerosis contribute to pathogenesis. For these stud-
ies, our initial experimental system employed athero-
sclerosis-prone mice (apoE-null animals in the
C57BL/6 background) treated with streptozotocin
(23), a β-cell toxin that causes insulin deficiency. In
contrast to euglycemic apoE-null mice, diabetic ani-
mals display advanced atherosclerosis already evident
by 14 weeks of age. Diabetic vasculature in the apoE-
null animals shows an increased number and area of
atherosclerotic lesions, as well as enhanced complexity,
with fibrous caps, cholesterol clefts, and necrosis. Lev-
els of AGEs and RAGE are increased in diabetic vascu-
lature, as is expression of tissue factor, VCAM-1, and
matrix metalloproteinases (MMPs) 2 and 9. To deter-
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Figure 1
Schematic depiction of RAGE-ligand interaction showing domains of the
receptor. The V-type domain is critical for binding of RAGE ligands. Dele-
tion of the cytosolic tail results in a modified form of RAGE that binds
ligands, remains firmly embedded in the cell membrane, but does not
transmit RAGE-mediated cellular activation. Even in the presence of
endogenous full-length RAGE, expression of dominant negative RAGE
blocks signaling from the receptor. sRAGE, soluble RAGE (extracellular
domain of RAGE); DN-RAGE, dominant negative RAGE (extracellular
domain + transmembrane-spanning domain).
Figure 2
Schematic depiction of a two-hit model of vascular perturbation
mediated by RAGE and its ligands. We hypothesize that the diabetic
vessel wall displays increased expression of RAGE ligands and the
receptor itself (first hit). In the presence of additional perturbation
(second hit), such as ischemic stress, immune/inflammatory stimuli,
physical stress, or modified lipoproteins, there is an exaggerated cel-
lular response promoting formation of vascular lesions (rather than
restitution of vascular homeostasis).
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mine whether blocking access of ligands to cell surface
RAGE affects the accelerated atherosclerosis seen in the
diabetic animals, we used a soluble, truncated form of
RAGE (sRAGE), spanning the receptor’s ligand-bind-
ing extracellular domain (Figure 1) (19). As low levels
of sRAGE are present in the plasma normally, we could
administer recombinant sRAGE to animals daily to
achieve microgram levels in the plasma without trig-
gering an immune response. We found that treatment
of diabetic apoE null mice with sRAGE suppressed the
accelerated pace of atherogenesis down to the level
observed in euglycemic controls in a dose-dependent
manner (23). Furthermore, lesion complexity in
sRAGE-treated diabetic mice was reduced, and the
remaining lesions were mostly fatty streaks, resembling
the level of complexity observed in euglycemic apoE-
null mice at the same early age.
Vessels from animals treated with sRAGE display
reduced levels of cellular RAGE and AGEs. AGEs can be
detected in the plasma complexed with sRAGE, but
such complexes do not appear to accumulate and are
presumed to be degraded. Inhibition of AGE-RAGE
interaction might also affect formation of AGEs, since
RAGE-mediated cellular activation promotes glycoxi-
dation and other manifestations of oxidant stress. As
the level of RAGE ligands in the vessel wall declines, so
does expression of RAGE and of vascular activation
markers associated with atherosclerosis. It is important
to note that the reduced pace of atherogenesis in dia-
betic mice treated with sRAGE does not involve changes
in glycemia or plasma cholesterol or triglycerides.
To determine whether our findings could be extrap-
olated to other experimental models, and to establish
a model system relevant to insulin resistance, we have
begun working with genetically diabetic (db/db) mice.
Our preliminary studies have shown that db/db animals
deficient in apoE display accelerated atherosclerosis
which can be suppressed by administration of sRAGE
(24), thus extending our results from the streptozo-
tocin-induced diabetes model (above). Blockade of
RAGE using sRAGE may therefore be broadly applica-
ble for treating atherogenesis in diabetic vasculature.
Amplification of the inflammatory response in
murine models of diabetic atherosclerosis, as a conse-
quence of the RAGE-ligand interaction, has also proven
applicable to the pathogenesis of tissue injury in other
settings of diabetic complications. Diabetic wounds are
well known to be slow to close, poor at forming granu-
lation tissue, and prone to sustained inflammation. We
have found that administration of sRAGE in a murine
diabetic wounding model leads to accelerated wound
closure most likely by decreasing expression of proin-
flammatory cytokines and matrix metalloproteinases,
and by augmenting levels of angiogenic factors (25). In
diabetic periodontal disease, impaired host response
mechanisms in the diabetic subject must contend with
invading Gram-negative pathogens as well as destruc-
tion of periodontal tissues by host effector pathways.
Blockade of RAGE in a murine model of diabetic peri-
odontal disease diminishes the loss of alveolar bone
while blocking the destructive inflammatory process
(26). Containment of the Gram-negative infection also
occurred effectively in the presence of sRAGE. These
results suggest that RAGE-ligand interaction provides
a chronic inflammatory pathway contributing to the
pathogenesis of diabetic complications. The conse-
quences of triggering such pathways include the recruit-
ment of inflammatory mediators and effector mole-
cules (for example, sustained expression of TNF-α, IL-1,
IL-6, and metalloproteinases) eventuating in accelerat-
ed tissue destruction. These considerations suggest the
possibility that blockade of RAGE could provide an
effective approach in a range of diabetic complications.
RAGE and cellular dysfunction in the amyloidoses
Deposition of amyloid in tissues displaces normal
structures and, at high concentrations, can exert non-
specific toxic effects on cells by disturbing the integri-
ty of membranes. The latter, traditional view of amy-
loid is being replaced by the concept that amyloid
deposits and low–molecular weight amyloid fragments
are biologically active via their interaction with specif-
ic cell surface receptors (27–31). Such receptors appear
to act early in the disease process when the amyloid
burden is low, possibly by amplifying the response to
nascent amyloid (Figure 3). RAGE binds β-sheet fibril-
lar material regardless of the composition of the sub-
units (amyloid-β peptide, Aβ, amylin, serum amyloid A,
and prion-derived peptides, among others) (27, 28),
and deposition of amyloid results in enhanced expres-
sion of RAGE. For example, in the brains of patients
with Alzheimer disease (AD), RAGE expression increas-
es in neurons and glia. The consequences of Aβ ligation
of RAGE appear to be quite different on neurons ver-
sus microglia. Whereas microglia become activated as
a consequence of Aβ-RAGE interaction, as reflected by
increased motility and expression of cytokines (27),
early RAGE-mediated neuronal activation is supersed-
ed by cytotoxicity at later times (33). Thus, in our pre-
liminary results, transgenic mice with targeted neu-
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Figure 3
Schematic depiction of a role for receptor-mediated interaction with path-
ogenic Aβ assemblies (which could be dimers, multimers, and/or fibrils) in
mediating cellular dysfunction early in amyloidoses (left). In contrast, non-
specific neuronal/cellular toxicity (for example, interfering with the integri-
ty of cell membranes) is likely to be an important mechanism of cellular
injury at later stages of the disease when there is a higher level of Aβ (right).
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ronal expression of RAGE and mutant amyloid pre-
cursor protein — the latter causing an Aβ-rich environ-
ment in the brain — display exaggerated cell stress at
3–5 months, including activation of NF-κB and expres-
sion of IL-6. At 8–10 months, cytotoxicity appears to be
increased (34). These preliminary findings are consis-
tent with RAGE-mediated amplification of the effects
of Aβ even prior to extensive amyloid deposition. Inhi-
bition of Aβ-induced cerebral vasoconstriction and
reduced transfer of the amyloid peptide across the
blood-brain barrier following receptor blockade pro-
vide further evidence of a role for RAGE in cellular
interactions with Aβ (35).
To analyze RAGE-amyloid interactions more direct-
ly, we have turned to a model of systemic amyloidosis
in which the effects of RAGE blockade can be assessed
(28). In the spleen, the distribution of amyloid A over-
laps closely with that of RAGE, which is especially
prominent in mononuclear phagocytes. Nuclear
extracts of splenic tissue showed NF-κB activation and
increased expression of heme oxygenase type 1, M-CSF,
and IL-6 (28). In contrast to Aβ amyloid, which is
sequestered behind the blood-brain barrier in AD, amy-
loid A and increased levels of cellular RAGE in the
spleen are accessible to sRAGE or anti-RAGE F(ab′)2
molecules. Following receptor blockade with these
agents, we observed decreased NF-κB activation and
reduced expression of cellular RAGE and cell stress
markers, as well as a loss of amyloid (28), suggesting
that interactions with RAGE induce or maintain both
the deposition of amyloid and the altered cellular prop-
erties seen in amyloid-rich environments.
Taken together, these data lead us to propose that
in amyloidoses the interaction of RAGE with patho-
logic Aβ species (as well as other amyloids) provides
an early event modulating properties of the vascula-
ture and neurons. This interaction also apparently
primes host response mechanisms through its effects
on cells of mononuclear phagocyte lineage.
RAGE and propagation 
of the immune/inflammatory response
Based on the emerging multiligand nature of RAGE, it
seemed unlikely that the receptor would solely interact
with AGEs and amyloid. We sought other
endogenous ligands present in tissues that
might engage the receptor, as a part of protective
host response mechanisms. As RAGE is most
abundant in the lung, we screened lung extracts
for polypeptides that bind specifically to RAGE.
These studies resulted in the identification of S100/cal-
granulins and amphoterin as ligands of RAGE (36).
The S100/calgranulins constitute a family of closely
related calcium-binding polypeptides containing two
EF-hand regions, linked by a connecting peptide (37).
Although they lack signal peptides, it has long been
known that S100/calgranulins gain access to the extra-
cellular space, especially at sites of chronic
immune/inflammatory responses, as in cystic fibrosis
and rheumatoid arthritis. Because the S100/calgran-
ulins appear to act as proinflammatory cytokines (37),
it was expected that specific cell surface receptors must
mediate their effects, and we have shown that RAGE
binds S100A12 (also termed EN-RAGE for extracellu-
lar, newly discovered RAGE ligand) and the related pro-
tein S100B, with nanomolar affinity (9). These findings
lead us to predict that RAGE is a receptor for many
members of the S100/calgranulin family, mediating
their proinflammatory effects on cells such as lym-
phocytes and mononuclear phagocytes. Indeed, addi-
tion of S100A12 to lymphocytes results in expression
of IL-2 and cell proliferation; mononuclear phagocytes
elaborate IL-1β and TNF-α under the same conditions
(9). An emerging view of RAGE in immune/inflamma-
tory responses is shown in Figure 4. We propose that
RAGE-S100 interaction provides a novel costimulato-
ry axis in which aggregates of S100 proteins bridge and
activate RAGE on lymphocytes and monocytes. Exper-
iments are underway to test this hypothesis.
The delayed-type hypersensitivity response provided
a logical model in which to test the effect of RAGE-
S100 interaction on cellular activation in the context of
immunity and inflammation. Animals sensitized and
challenged with methylated BSA, which is not a ligand
of RAGE, show marked lower-extremity swelling and
infiltration of the tissue with inflammatory cells, as
well as activation of NF-κB and expression of proin-
flammatory cytokines. Levels of S100/calgranulins and
RAGE in these inflammatory lesions are also striking-
ly increased. Administration of sRAGE to animals at
the time of the challenge dose of methylated albumin
strikingly decreases infiltration of the tissue by
immune/inflammatory effector cells, as well as other
associated changes (edema, expression of cytokines,
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Figure 4
Schematic depiction of a role for RAGE and its ligands (espe-
cially S100/calgranulins) at the site of a chronic immune/inflam-
matory response. We hypothesize that S100/calgranulin-RAGE
interaction provides a mechanism amplifying the inflammatory
response by mediating activation of RAGE-bearing cells, includ-
ing mononuclear phagocytes, lymphocytes, and cells in the ves-
sel wall. In contrast, RAGE and its ligands are not the trigger for
initiating the host response, which may be due to primary
immune, inflammatory, or infectious stimuli.
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etc.) (9). Blocking antibodies to S100 proteins or to
RAGE itself also suppress pathologic changes, and the
most prominent suppression is observed following
treatment with both antibodies together, presumably
because the dual treatment allows a more complete
blockade of RAGE-ligand interaction.
These results suggested that RAGE interactions with
ligands such as the S100/calgranulins play a proximal
role in the inflammatory cascade. For example, preven-
tion of NF-κB activation and the generation of IL-2 and
TNF-α are critical early events leading to delayed-type
hypersensitivity (9). Prompted by our observations on
delayed-type hypersensitivity, we extended our studies
to other models, such as colitis in IL-10–null mice, col-
lagen-induced arthritis, and experimental autoimmune
encephalitis. Administration of sRAGE to IL-10–defi-
cient mice suppresses the development of colitis and
associated findings. Indeed, histologic studies show
decreased cryptitis, diminished nuclear binding activi-
ty for NF-κB in nuclear extracts of colons, and reduced
systemic levels of TNF-α (9). Our pilot studies in colla-
gen-induced arthritis demonstrate a similar suppres-
sion of the inflammatory response in animals treated
with sRAGE. In each case, it appears that antagonism of
RAGE interferes with the effector stage of the disease,
rather than the initial priming of lymphocytes. Further
studies will be required to elucidate how RAGE con-
tributes to the biology of lymphocytes and mononu-
clear phagocytes, but the current findings suggest that
RAGE-S100/calgranulin interaction represents a 
potentially important axis capable of amplifying
immune/inflammatory responses.
RAGE and amphoterin: implications 
for tumor biology
Amphoterin is a high-mobility group I nonhistone
chromosomal DNA-binding protein (38). As such, it is
found in the nucleus, although its role in chromosomal
structure and function is not fully understood. As with
the S100/calgranulins, amphoterin is found, unexpect-
edly, in the extracellular space, where it is prominent
during certain stages of development (38). ECM-associ-
ated amphoterin promotes neurite outgrowth and pro-
vides a surface for assembly of protease complexes in the
fibrinolytic system, which can contribute to cell mobil-
ity. We have found that amphoterin-induced neurite
outgrowth is mediated by RAGE (36), and studies of
Huttunen et al. (38) have revealed that ligation of this
receptor activates two small GTPases of the Rho family,
Cdc42 and Rac, which are implicated in cytoskeletal
remodeling in cell movement.
In view of increased expression of amphoterin and
RAGE in tumors, we considered that the tumor bed
might be an ideal locus to study the effect of ampho-
terin-RAGE interaction on cell migration and invasion
(10). In a primary tumor model (C6 glioma), adminis-
tration of anti-RAGE F(ab′)2 or sRAGE partially inhibits
local tumor growth. Furthermore, stable transfectants
of C6 glioma cells that overexpress wild-type RAGE pro-
duced larger and more invasive tumors than do parental
C6 cells. Conversely, cells expressing a dominant nega-
tive form of RAGE or sRAGE produce only very small
tumors, indicating that blockade of RAGE function
strongly suppresses tumor growth, as has also been
observed in the Lewis lung metastasis model (10). More-
over, in that latter model, when animals are treated with
sRAGE at the time the primary tumor is excised, lung
metastases are barely detectable, although they are read-
ily apparent in vehicle-treated mice. Finally, in an
endogenous tumor model, spontaneously arising papil-
lomas in mice expressing v-Ha-ras (39), administration
of sRAGE markedly suppressed the development of
papillomas. The major effect of RAGE appears to be on
tumor cell migration and invasiveness, rather than
apoptosis or proliferation, although RAGE blockade
can also reduce cell growth. Consistent with this
impression, increased levels of MMPs 2 and 9, which are
closely associated with tumor cell invasion, are detected
in tumors derived from cells bearing wild-type RAGE
but not in those in which RAGE is blocked.
In vitro studies were performed to gain further
insights into mechanisms underlying the antitumor
effect of blocking RAGE (10). Cultured C6 glioma cells
show a striking difference in morphology and activation
of intracellular signalling pathways when plated on
amphoterin-coated matrices, depending on whether
they overexpress wild-type RAGE or carry dominant
negative RAGE. The former cells adhere to the surface
and extend long processes, whereas the latter are round-
ed with little extension of cellular processes. In cellular
invasion assays, C6 cells bearing wild-type RAGE show
enhanced penetration of Matrigel. In the presence of
amphoterin they activate the mitogen-activated protein
kinase pathway components p38, stress-activated pro-
tein kinase, and extracellular signal–regulated protein
kinase (erk1/2), a response that is strikingly diminished
in cells bearing DN-RAGE or expressing sRAGE. These
studies suggest that RAGE binding to amphoterin in
the tumor bed enhances cell migration and invasion. In
contrast, RAGE-ligand interactions do not appear to
markedly alter tumor cell viability or angiogenesis.
RAGE blockade may therefore dovetail well with cyto-
toxic or antiangiogenic therapies.
Summation and hypotheses
At first glance, it seems difficult to fathom how one
receptor could be involved in an adverse manner, at least
with respect to restitution of homeostasis, in so many
and such diverse situations. It seems likely that RAGE
has escaped evolutionary pressure, or it would have long
ago been eliminated or markedly changed. Probably
because the RAGE pathway contributes to chronic dis-
orders occurring later in life, the receptor has remained
in the genome. For example, the deposition of AGEs in
diabetic tissues, the accumulation of amyloid in
Alzheimer brain, and the persistent presence of
S100/calgranulins at sites of chronic inflammation
drive receptor expression and, thereby, the subsequent
cellular responses. Here, the ligand appears to dictate
the biology of the receptor in that the presence of ligand
triggers expression of the receptor and the ensuing cel-
lular response. As far as we know, this response can only
be suppressed by intercepting RAGE-ligand interaction,
as occurs in the presence of sRAGE or blocking anti-
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bodies to the receptor. Alternatively, RAGE may have
been retained in the genome because of as-yet unrecog-
nized cytoprotective properties (see below).
It is important to note that ligand-RAGE interaction
can have strikingly different consequences on differ-
ent cell types. Thus, the interaction of Aβ with RAGE
on microglia stimulates chemotaxis and expression of
cytokines (for example, TNF-α) (27). On neurons and
neuron-like RAGE-bearing cells, shortly after exposure
to ligands, NF-κB is activated and leads to heightened
expression of cell stress–associated proteins. At later
times, the same cells may be forced down an apopto-
sis-like pathway (33). This difference in the outcome
may reflect the capacity of each cell type to respond to
cell stress signals — for example, those generated by
oxidants and/or other toxic intermediates — or may
arise from cell type–specific expression of coreceptors
or signaling molecules.
Our findings suggest that RAGE will be primarily
involved not as a causative or initiating factor for dis-
eases such as diabetes or Alzheimer disease but rather
as a mediator of the subsequent effects of chronic cel-
lular activation such as cellular dysfunction and tissue
destruction. Thus, antagonism of RAGE might be
advantageous for arresting or ameliorating a range of
pathophysiologically relevant disorders. In this regard,
it will be important to understand the fine structure
of receptor-ligand interaction. For example, although
the macromolecular ligands of RAGE cross-compete
for binding to the receptor, it is unclear whether they
interact with identical portions of the V-domain, or
whether there is a large binding pocket with multiple
closely situated subdomains optimally fitting differ-
ent ligand-bearing structures.
It is to be expected that there will be commonalities
of structure that these otherwise seemingly diverse lig-
ands assume in order to interact with RAGE, and
indeed, all of the ligands studied so far appear to be
multivalent. For instance, nonenzymatic glycation can
modify more than one group on a single macromole-
cule. The formation of intermolecular crosslinks by the
same process (4) further increases the number of poten-
tial modification sites on a particular protein. Similar-
ly, S100/calgranulins readily aggregate, and their activ-
ity has most often been observed after formation of a
multimeric structure (37). Finally, β-sheet fibrils are
ideally suited to rearrange the surface topology of cells
with which they interact because of the density of pos-
sible ligand sites on any individual fiber. In each case, it
is important to consider the possibility that one of
these ligand-bearing structures crosslinks RAGE on one
cell type, maximizing the cellular response, or that it
might bridge two RAGE-bearing cells. In the latter case,
RAGE might function as a costimulatory molecule, per-
haps by bridging mononuclear phagocytes and T lym-
phocytes via S100/calgranulins that engage RAGE pro-
teins on the surface of each cell. Such an interaction
would be analogous to B7-1/B7-2 interaction with
CD28 (in the case of macrophage lymphocyte interac-
tion in immunity) (40), except that the relative abun-
dance and soluble nature of S100/calgranulins might
provide a certain level of nonspecificity (and augmen-
tation) of cellular activation in the ensuing im-
mune/inflammatory response. Another possible con-
sequence of this promiscuous multivalency of RAGE
ligands might be the recruitment of coreceptors, which
could contribute to subsequent cellular events. For
example, Aβ interacts with several cell surface binding
sites in addition to RAGE (27); the latter include type A
scavenger receptors (29), α-7 nicotinic acetylcholine
receptors (30), heparin-like proteoglycans (32), and neu-
rotrophin receptors (31), among others. Future studies
are in progress on many levels to address questions
regarding structure-function relationships central to
the properties of RAGE, and the extent to which the
receptor regulates cell-cell crosstalk, as well as possible
interactions with coreceptors.
It is also to be expected that there are situations where
the receptor will exert a beneficial effect, probably via
the same inflammatory pathways. For example, it is very
possible that an ancient structure borne by microor-
ganisms, but not yet identified, will interact with RAGE,
consistent with the placement of this receptor in the
innate immune system. RAGE probably does not func-
tion as an endocytic pattern-recognition receptor like
SR-A (see Platt and Gordon, this Perspective series, ref.
41; and refs. 1, 2, 42, 43) but rather may serve as a 
signaling receptor that can drive subsequent im-
mune/inflammatory events, as the Toll-like receptors,
another family of pattern-type receptors, are believed to
do (43). RAGE may also exert a beneficial role in limit-
ed inflammatory responses, in which ligands are pres-
ent only briefly. In peripheral nerve injury, such as a sci-
atic nerve crush model which we have begun to study,
blocking ligand-RAGE interaction actually delays tissue
repair (44). In this context, nerve injury is associated
with a rapid and transient rise in S100/calgranulins and
amphoterin at the site of damage, resulting in local
upregulation of RAGE. The enhanced expression of
RAGE in the injured nerve follows closely the time
course for ligands of the receptor and, thus, is also quite
brief. Blocking RAGE-ligand interaction in the injured
nerve appears to damp critical inflammatory mecha-
nisms that are necessary for disposal of myelin debris at
the damage site and subsequent remyelination, as well
as for decreasing neurite outgrowth. Although this
model of peripheral nerve injury may prove limited in
its applicability to human disease, it does suggest a way
in which RAGE-mediated processes can be beneficial in
repair. Though there is much more to be learned about
the contribution of RAGE to health and disease, these
results provide an outline mapping properties of an
intriguing multiligand member of the immunoglobu-
lin superfamily of cell surface molecules.
Acknowledgments
This work was supported by grants from the USPHS
(HL-60901, AG-17490, AG-16223), the Juvenile Dia-
betes Research Foundation, the Greenwall Foundation,
the Burroughs Wellcome Trust, and the Surgical
Research Fund. Please note that, due to restrictions on
the number of references permitted by JCI policy, the
reference list is quite narrow; it is not meant in any way
to diminish the contribution of references not cited.
954 The Journal of Clinical Investigation | October 2001 | Volume 108 | Number 7
Downloaded from http://www.jci.org on May  4, 2015.   http://dx.doi.org/10.1172/JCI14002
1. Hampton, R., Golenbock, D., Penman, M., Krieger, M., and Raetz, C.
1991. Recognition and plasma clearance of endotoxin by scavenger
receptors. Nature. 352:342–344.
2. Fraser, I., Koziel, H., and Ezekowitz, R. 1998. The serum mannose-bind-
ing protein and the macrophage mannose receptor are pattern recog-
nition molecules that link innate and adaptive immunity. Semin.
Immunol. 10:363–372.
3. Medzhitov, R., and Janeway, C. 2000. Innate Immunity. N. Engl. J. Med.
343:338–344.
4. Brownlee, M. 1995. Advanced glycosylation in diabetes and aging. Annu.
Rev. Med. 46:223–234.
5. Miyata, T., et al. 1996. RAGE mediates the interaction of AGE-beta-2-
microglobulin with human mononuclear phagocytes via an oxidant-
sensitive pathway: implications for the pathogenesis of dialysis-related
amyloidosis. J. Clin. Invest. 98:1088–1094.
6. Schmidt, A.-M., Yan, S.-D., and Stern, D.M. 1995. The dark side of glu-
cose. Nat. Med. 1:1002–1004.
7. Schmidt, A.M., et al. 1992. Isolation and characterization of binding
proteins for advanced glycosylation endproducts from lung tissue
which are present on the endothelial cell surface. J. Biol. Chem.
267:14987–14997.
8. Neeper, M., et al. 1992. Cloning and expression of RAGE: a cell surface
receptor for advanced glycosylation end products of proteins. J. Biol.
Chem. 267:14998–15004.
9. Hofmann, M., et al. 1999. RAGE mediates a novel proinflammatory
axis: the cell surface receptor for S100/calgranulin polypeptides. Cell.
97:889–901.
10. Taguchi, A., et al. 2000. Blockade of RAGE/amphoterin suppresses
tumor growth and metastases. Nature. 405:354–360.
11. Li, J., and Schmidt, A.-M. 1997. Characterization and functional analy-
sis of the promoter of RAGE. J. Biol. Chem. 272:16498–16506.
12. Li, J., Qu, W., and Schmidt, A.-M. 1998. Sp1 binding elements in the
promoter of RAGE are essential for amphoterin-mediated gene expres-
sion in cultured neuroblastoma cells. J. Biol. Chem. 273:30870–30878.
13. Tanaka, N., et al. 2000. RAGE is induced by the glycation products
themselves and TNF-alpha through NF-kB and by 17β-estradiol
through Sp1 in human vascular endothelial cells. J. Biol. Chem.
275:25781–25790.
14. Kislinger, T., et al. 1999. N(epsilon)-(carboxymethyl)lysine adducts of
proteins are ligands for RAGE that activate cell signaling pathways and
modulate gene expression. J. Biol. Chem. 274:31740–31749.
15. Bierhaus, A., et al. 1997. AGE-mediated induction of tissue factor in cul-
tured endothelial cells is dependent on RAGE. Circulation.
46:1481–1490.
16. Yamagishi, S., et al. 1997. AGE-driven angiogenesis in vitro. Induction
of the growth and tube formation of human microvascular endothelial
cells through autocrine vascular endothelial growth factor. J. Biol. Chem.
272:8723–8730.
17. Yamagishi, S., Fujimori, H., Yonekura, H., Yamamoto, Y., and Yamamo-
to, H. 1998. AGEs inhibit prostacyclin production and induce PAI-1 in
human microvascular endothelial cells. Diabetologia. 41:1435–1441.
18. Wautier, J.L., et al. 1996. Receptor-mediated endothelial cell dysfunc-
tion in diabetic vasculopathy: soluble RAGE blocks hyperpermeability.
J. Clin. Invest. 97:238–243.
19. Schmidt, A.-M., et al. 1994. RAGE has a central role in vessel wall inter-
actions and gene activation in response to AGEs. Proc. Natl. Acad. Sci.
USA. 91:8807–8811.
20. Schmidt, A.-M., et al. 1995. Advanced glycation endproducts interact-
ing with their endothelial receptor induce expression of VCAM-1 in cul-
tured human endothelial cells and in mice. J. Clin. Invest. 96:1395–1403.
21. Yan, S.D., et al. 1994. Enhanced cellular oxidant stress by the interac-
tion of AGEs with their receptors/binding proteins. J. Biol. Chem.
269:9889–9897.
22. Schmidt, A.M., et al. 1993. Regulation of human mononuclear phago-
cyte migration by cell surface binding proteins for AGEs. J. Clin. Invest.
91:2155–2168.
23. Park, L., et al. 1998. Suppression of accelerated diabetic atherosclerosis
by soluble receptor for AGE (sRAGE). Nat. Med. 4:1025–1031.
24. Wendt, T., et al. 2000. Accelerated atherosclerosis and vascular inflam-
mation develop in apoE null mice with type 2 diabetes. Circulation.
102(Suppl. II):1124. (Abstr.)
25. Goova, M., et al. 2001. Blockade of RAGE restores effective wound heal-
ing in diabetic mice. Am. J. Pathol. 159:513–525. 
26. Lalla, E., et al. 2000. Blockade of RAGE suppresses periodontitis-asso-
ciated alveolar bone loss in diabetic mice. J. Clin. Invest. 105:1117–1124. 
27. Yan, S.-D., et al. 1996. RAGE and amyloid-beta peptide neurotoxicity in
Alzheimer’s disease. Nature. 382:685–691.
28. Yan, S.-D., et al. 2000. Receptor-dependent cell stress and amyloid accu-
mulation in systemic amyloidosis. Nat. Med. 6:643–651.
29. Paresce, D.M., Ghosh, R.N., and Maxfield, F.R. 1996. Microglial cells
internalize aggregates of the Alzheimer’s disease amyloid beta-protein
via a scavenger receptor. Neuron. 17:553–565.
30. Wang, H.-Y., et al. 2000. Aβ(1-42) binds to α-7 nicotinic acetylcholine
receptor with high affinity. J. Biol. Chem. 275:5626–5632.
31. Yaar, M., et al. 1997. Binding of beta-amyloid to the p75 neurotrophin
receptor induces apoptosis. J. Clin. Invest. 100:2333–2340.
32. Giulian, D., et al. 1998. The HHQK domain of beta-amyloid provides a
structural basis for the immunopathology of Alzheimer’s disease. J. Biol.
Chem. 273:29719–29726.
33. Sousa, M., et al. 2001. Familial amyloid polyneuropathy: RAGE-depend-
ent triggering of neuronal inflammatory and apoptotic pathways. J.
Neurosci. In press. 
34. Stern, D., et al. 2000. Enhanced neuronal stress in double transgenic
mice with targeted overexpression of RAGE and mutant APP. Society
for Neuroscience Abstract 351-#491.14.
35. Kumar, S., et al. 2000. RAGE at the blood-brain barrier mediates neu-
rovascular dysfunction caused by amyloidβ1-40 peptide. Society for
Neuroscience Abstract 141-#275.19.
36. Hori, O., et al. 1995. RAGE is a cellular binding site for amphoterin:
mediation of neurite outgrowth and co-expression of RAGE and
amphoterin in the developing nervous system. J. Biol. Chem.
270:25752–25761.
37. Schafer, B., and Heizmann, C. 1996. The S100 family of EF-hand calci-
um-binding proteins: functions and pathology. Trends Biochem. Sci.
21:134–140.
38. Huttunen, H., Fages, C., and Rauvala, H. 1999. RAGE-mediated neurite
outgrowth and activation of NF-kB require the cytoplasmic domain of
the receptor but different downstream signaling pathways. J. Biol. Chem.
274:19919–19924.
39. Leder, A., Kuo, A., Cardiff, R., Sinn, F., and Leder, P. 1990. V-Ha-ras
transgene abrogates the initiation step in mouse skin tumorigenesis:
effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA.
87:9178–9182.
40. June, C., Bluestone, J., Nadler, L., and Thompson, C. 1994. B7 and CD28
receptor families. Immunol. Today. 15:321–331.
41. Platt, N., and Gordon, S. 2001. Is the class A macrophage scavenger
receptor (SR-A) multifunctional? — The mouse’s tale. J. Clin. Invest.
108:649–654.
42. Krieger, M., and Herz, J. 1994. Structures and functions of multiligand
lipoprotein receptors: macrophage scavenger receptors and LDL recep-
tor-related protein. Annu. Rev. Biochem. 63:601–637.
43. Rock, F., Hardiman, G., Timans, J., Kastelein, R., and Bazan, J. 1998. A
family of human receptors structurally related to Drosophila Toll. Proc.
Natl. Acad. Sci. USA. 95:588–593.
44. Rong, L., et al. 2000. RAGE and its ligands, EN-RAGEs and amphoterin
are expressed in injured peripheral nerve and modulate regeneration in
a murine model of unilateral sciatic nerve crush. Society for Neuro-
science Abstract 58-#114.4.
The Journal of Clinical Investigation | October 2001 | Volume 108 | Number 7 955
Downloaded from http://www.jci.org on May  4, 2015.   http://dx.doi.org/10.1172/JCI14002
